Vi-Typhoid Conjugate Vaccine (Vi-TCV)

BIOLOGICAL2 trials

Sponsors

University of Maryland, Baltimore

Conditions

Typhoid

Phase 2

Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso

CompletedNCT03614533

University of Maryland, BaltimoreTyphoid

Start: 2018-12-03End: 2024-08-22Updated: 2025-05-30

Phase 3

Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi

Active, not recruitingNCT03299426

University of Maryland, BaltimoreTyphoid

Start: 2018-02-21End: 2025-10-30Target: 30000Updated: 2025-05-30

Related Papers

Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.

2024-01-2545 citations

Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.

2022-09-0127 citations

Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children

New England Journal of Medicine2021-09-15134 citations

A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

Clinical Infectious Diseases2019-01-099 citations

Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi

Clinical Infectious Diseases2019-01-0833 citations